S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

VolitionRx Stock Forecast, Price & News

-0.02 (-0.61%)
(As of 12/8/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
84,418 shs
Average Volume
242,098 shs
Market Capitalization
$174.53 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive VNRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VolitionRx logo

About VolitionRx

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Austin, TX.


VolitionRX Ltd (VNRX) Q3 2021 Earnings Call Transcript
November 12, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
Diagnostic substances
Current Symbol
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$10 thousand
Price / Sales
Book Value
$0.40 per share


Net Income
$-20.35 million
Net Margins
Pretax Margin




Free Float
Market Cap
$174.53 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.13 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

VolitionRx (NYSEAMERICAN:VNRX) Frequently Asked Questions

Is VolitionRx a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VolitionRx stock.
View analyst ratings for VolitionRx
or view top-rated stocks.

When is VolitionRx's next earnings date?

VolitionRx is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for VolitionRx

How were VolitionRx's earnings last quarter?

VolitionRx Limited (NYSEAMERICAN:VNRX) released its earnings results on Wednesday, November, 10th. The medical research company reported ($0.13) EPS for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.02. VolitionRx had a negative net margin of 28,471.43% and a negative trailing twelve-month return on equity of 100.42%.
View VolitionRx's earnings history

What price target have analysts set for VNRX?

2 equities research analysts have issued 12 month price targets for VolitionRx's shares. Their forecasts range from $8.00 to $9.00. On average, they expect VolitionRx's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 160.7% from the stock's current price.
View analysts' price targets for VolitionRx
or view top-rated stocks among Wall Street analysts.

Who are VolitionRx's key executives?

VolitionRx's management team includes the following people:
  • Cameron John Reynolds, President, Chief Executive Officer & Director
  • Gaetan Michel, Chief Operating Officer
  • Terig Hughes, Chief Financial Officer & Treasurer
  • Jason Bradley Terrell, Chief Medical Officer & Head-US Operations
  • Jacob Vincent Micallef, Chief Scientific Officer

What other stocks do shareholders of VolitionRx own?

What is VolitionRx's stock symbol?

VolitionRx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

Who are VolitionRx's major shareholders?

VolitionRx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Lagoda Investment Management L.P. (5.72%), Morgan Stanley (1.09%), BlackRock Inc. (1.01%), Geode Capital Management LLC (0.51%), Renaissance Technologies LLC (0.24%) and Millennium Management LLC (0.12%). Company insiders that own VolitionRx stock include Cameron John Reynolds, Guy Archibald Innes, Jason Bradley Md Terrell, Kim Nguyen, Martin Charles Faulkes and Salvatore Thomas Butera.
View institutional ownership trends for VolitionRx

Which institutional investors are selling VolitionRx stock?

VNRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Morgan Stanley, BlackRock Inc., Dimensional Fund Advisors LP, and Citadel Advisors LLC.
View insider buying and selling activity for VolitionRx
or view top insider-selling stocks.

Which institutional investors are buying VolitionRx stock?

VNRX stock was bought by a variety of institutional investors in the last quarter, including Lagoda Investment Management L.P., Wolverine Trading LLC, Geode Capital Management LLC, and Cowen Prime Advisors LLC. Company insiders that have bought VolitionRx stock in the last two years include Cameron John Reynolds, Guy Archibald Innes, Kim Nguyen, and Salvatore Thomas Butera.
View insider buying and selling activity for VolitionRx
or or view top insider-buying stocks.

How do I buy shares of VolitionRx?

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VolitionRx's stock price today?

One share of VNRX stock can currently be purchased for approximately $3.26.

How much money does VolitionRx make?

VolitionRx has a market capitalization of $174.53 million and generates $10 thousand in revenue each year. The medical research company earns $-20.35 million in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does VolitionRx have?

VolitionRx employs 65 workers across the globe.

What is VolitionRx's official website?

The official website for VolitionRx is www.volitionrx.com.

Where are VolitionRx's headquarters?

How can I contact VolitionRx?

VolitionRx's mailing address is 13215 BEE CAVE PARKWAY GALLERIA OAKS B SUITE 125, AUSTIN TX, 78738. The medical research company can be reached via phone at (646) 650-1351, via email at [email protected], or via fax at 65 32 8172 5651.

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.